SCHEMBL4115137

SCHEMBL4115137

O=C(CCCCCN(CC(=O)N1CCCCC1)CC(=O)N1CCCCC1)NO

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 11/20 0.44
HDAC8 Q9BY41 7/20 0.44
HDAC3 O15379 7/20 0.44
HDAC2 Q92769 7/20 0.44
HDAC6 Q9UBN7 5/20 0.44
HDAC5 Q9UQL6 1/20 0.44
NCOR2 Q9Y618 4/20 0.43
L3MBTL1 Q9Y468 2/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ATM Q13315 1/20 0.41
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HSP90AA1 P07900 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3997411 0.86 HDAC1 (0.43) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL15480397 0.82 ATM (0.61) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL12395359 0.81 ATM (0.63) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL4130240 0.79 HDAC1 (0.60) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL4123769 0.75 HDAC1 (0.58) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL4131217 0.75 HDAC1 (0.59) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL13965318 0.75 HDAC1 (0.59) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL30299404 0.73 L3MBTL1 (0.56) L3MBTL1MEN1KMT2ATDP1ATM
SCHEMBL8284495 0.72 HDAC1 (0.69) HDAC1HDAC8HDAC3HDAC2HDAC6
SCHEMBL3994611 0.70 HDAC1 (0.53) HDAC1HDAC8HDAC3HDAC2HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1694329-A4 DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATES ATON PHARMA INC (US) 2009-06-03 EP disclosed
US-20090023718-A1 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives ATON PHARMA, INC. (US) 2009-01-22 US disclosed
US-20090023718-A1 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives ATON PHARMA, INC. (US) 2009-01-22 US disclosed
US-20090023718-A1 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives ATON PHARMA, INC. (US) 2009-01-22 US disclosed
EP-1694329-A2 DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATES Aton Pharma, Inc. (US) 2006-08-30 EP disclosed
WO-2005053610-A2 DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATIVES ATON PHARMA, INC. (US) 2005-06-16 WO disclosed
WO-2005053610-A2 DIAMINE AND IMINODIACETIC ACID HYDROXAMIC ACID DERIVATIVES ATON PHARMA, INC. (US) 2005-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023718-A1 Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives AADAC, BRDT, HDAC5 HDAC1 5/4885HDAC8 36/4885HDAC3 15/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.